Deuterated Caffeine Composition for Reduced Peak-Related Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Caffeine's pharmacokinetic profile, characterized by high maximal plasma concentration (Cmax), short time to maximal plasma concentration (Tmax), and rapid clearance, leads to significant adverse effects such as anxiety, insomnia, gastrointestinal issues, and addiction, limiting its widespread use.
Innovation Solution
Compositions comprising deuterated caffeine, which replaces hydrogen atoms with deuterium, offering a modified pharmacokinetic profile with lower Cmax values, longer half-life, and longer Tmax, reducing adverse effects while maintaining caffeine's beneficial attributes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If caffeine is administered to achieve CNS stimulation and therapeutic effects, then beneficial attributes such as improved wakefulness, concentration, and motor coordination are achieved, but adverse effects including anxiety, insomnia, gastrointestinal issues, and addiction occur due to high Cmax and rapid clearance
Solution Approach 1:
The patent applies parameter changes by replacing hydrogen atoms with deuterium atoms in the caffeine molecule. This isotopic substitution modifies the pharmacokinetic parameters of caffeine, specifically reducing Cmax values, extending half-life, and prolonging Tmax. These parameter changes allow the compound to maintain therapeutic efficacy while reducing adverse effects associated with rapid clearance and high peak concentrations
2Duration of action of moving object
If caffeine is administered to achieve sustained CNS stimulation, then therapeutic benefits are maintained, but the short half-life and rapid clearance limit the duration of action and require frequent dosing
Solution Approach 1:
The deuterium substitution changes the metabolic parameter of clearance rate. The C13-labeled and deuterated caffeine compounds exhibit reduced clearance rates compared to conventional caffeine, resulting in extended half-life and prolonged duration of action. This allows for sustained CNS stimulation with less frequent dosing
3Speed
If conventional caffeine is used to achieve rapid CNS effects, then quick onset of action is achieved, but the short Tmax leads to rapid peak and crash cycles causing adverse effects
Solution Approach 1:
The isotopic labeling with deuterium and C13 modifies the time-related pharmacokinetic parameters. The deuterated caffeine compounds demonstrate extended Tmax values, which smooths the concentration-time profile and reduces the magnitude and rapidity of the peak-crash cycles that cause adverse effects, while still maintaining adequate onset speed for therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Deuterated caffeine compositions reduce side effects like anxiety, insomnia, and gastrointestinal issues, while providing sustained action and increased patient compliance, with similar plasma and central nervous system exposure as non-isotopically enriched caffeine.
Implementation Method 1
deuterated caffeine, which replaces hydrogen atoms with deuterium, offering a modified pharmacokinetic profile with lower Cmax values, longer half-life, and longer Tmax
Data Source
AI summary
Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.